amneal pharmaceuticals inc’s stock amrx soared 14 in premarket trade monday after the generics and specialty pharmaceuticals company offered firstquarter guidance that topped consensus estimates bridgewater njbased amneal said it expects revenue for the quarter to range from 550 million to 560 million up about 12 from the yearearlier quarter and above the 529 million factset consensus the company is expecting its pretax loss to range from 10 million to breakeven an improvement of about 50 from a year ago the company’s longterm debt is expected to stand at 2692 billion at quarterend while cash is expected to stand at 151 million resulting in net debt of 2541 billion down from 2647 billion as of yearend 2022 for 2023 the company is expecting revenue of 225 billion to 235 billion compared with a factset consensus of 232 billion it expects adjusted eps of 40 cents to 50 cents while factset is expecting 50 cents the stock has fallen 67 in the last 12 months while the sp 500 spx has fallen 58